日本ケミファ(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|---|---|---|
東証STD | 医薬品 | 4539/E00957 | NIPPON CHEMIPHAR CO., LTD. |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|---|---|---|---|---|---|---|---|---|
2023/05/19 | 日証協 | 53,544株 | -1.29% | 400株 | 0% | 70,353株 | -1.26% | 20,701株 | -0.48% |
2023/05/12 | 日証協 | 54,244株 | -2.52% | 400株 | 0% | 71,252株 | -2.6% | 20,801株 | +114.58% |
2023/05/02 | 日証協 | 55,644株 | -12.16% | 0株 | -100% | 73,151株 | -9.4% | 9,694株 | -54.08% |
2023/04/28 | 日証協 | 63,347株 | -4.09% | 200株 | 0% | 80,744株 | -3.93% | 21,110株 | -11.73% |
2023/04/21 | 日証協 | 66,047株 | -1.3% | 200株 | -99.56% | 84,044株 | -1.14% | 23,914株 | +67.23% |
2023/04/14 | 日証協 | 66,918株 | +1.24% | 45,400株 | +1330.82% | 85,015株 | -3.95% | 14,300株 | +91.64% |
2023/04/07 | 日証協 | 66,099株 | -2.69% | 3,173株 | -78.61% | 88,515株 | +33.28% | 7,462株 | -80.01% |
2023/03/31 | 日証協 | 67,929株 | +25.53% | 14,832株 | +78.46% | 66,414株 | -31.91% | 37,325株 | +153.95% |
2023/03/24 | 日証協 | 54,114株 | +1.66% | 8,311株 | +62.8% | 97,543株 | +7.61% | 14,698株 | +52.64% |
2023/03/17 | 日証協 | 53,231株 | -5.81% | 5,105株 | -52.32% | 90,641株 | +0.26% | 9,629株 | -39.13% |
2023/03/10 | 日証協 | 56,513株 | -0.22% | 10,706株 | +44.52% | 90,408株 | -0.04% | 15,820株 | +14.96% |
2023/03/03 | 日証協 | 56,635株 | -8.7% | 7,408株 | +288.67% | 90,445株 | +1.33% | 13,761株 | +145.86% |
2023/02/24 | 日証協 | 62,035株 | -1.11% | 1,906株 | -38.52% | 89,258株 | -9.98% | 5,597株 | -29.12% |
2023/02/17 | 日証協 | 62,731株 | -2.03% | 3,100株 | -83.24% | 99,155株 | +0.41% | 7,897株 | -74.44% |
2023/02/10 | 日証協 | 64,031株 | -31.83% | 18,500株 | -53.56% | 98,754株 | -26.17% | 30,893株 | -47.06% |
2023/02/03 | 日証協 | 93,935株 | +41.79% | 39,833株 | -24.13% | 133,756株 | +26.72% | 58,355株 | +134.79% |
2023/01/27 | 日証協 | 66,248株 | -3.5% | 52,504株 | +267.01% | 105,550株 | -7.86% | 24,854株 | +10.15% |
2023/01/20 | 日証協 | 68,648株 | -4.59% | 14,306株 | -37.27% | 114,548株 | +0.79% | 22,564株 | +50.42% |
2023/01/13 | 日証協 | 71,948株 | -1.77% | 22,807株 | +77.9% | 113,648株 | -5.57% | 15,001株 | +45.7% |
※株式分割は考慮していませんのでご注意ください。